Cantor Fitzgerald adjusted its outlook on Amgen shares (NASDAQ:AMGN), reducing the price target from the previous $405.00 to $340.00. Despite the lowered price target, the firm maintained its ...

Shares of Amgen started crashing in early November and didn’t improve when the company released data from a Phase 2 clinical trial for its weight-loss candidate MariTide. That plunge has set the ...

As Amgen (NASDAQ:AMGN) shares are down 9% following the release of highly anticipated phase 2 data on its weight loss drug MariTide, Street analysts are weighing in. And there's a theme ...

Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in – but the highly anticipated doesn't seem to have lived up to investor expectations. MariTide (maridebart ...

Shares of Amgen (Nasdaq: AMGN) started crashing in early November and didn’t improve when the company released data from a phase 2 clinical trial for its weight-loss candidate MariTide.

Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone mineral density that could undermine its ability to compete in the fast ...

David Jagielski (Amgen): Shares of Amgen started crashing in late November following the release of data from a phase 2 clinical trial for its weight loss candidate, MariTide. I think that plunge ...

Results from a double-blind, dose-ranging phase 2 study of maridebart cafraglutide (MariTide, Amgen) were presented at the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease.

Its pipeline progress, especially its obesity drug MariTide, positions Amgen, Inc. (NASDAQ:AMGN) for long-term growth. The company’s move towards rare diseases exhibited strong momentum in late ...

Researchers presented results from a phase 2 study of maridebart cafraglutide (MariTide, Amgen) — an investigational injectable GLP-1 receptor agonist/GIP receptor antagonist — that showed a ...